drugset / Trial / NCT03744949
ED50 and ED95 of Remifentanil for Intubation Without NOL Variation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Our aim, in this study, is to elucidate the optimal dosing range (ED50 and ED95) of bolus remifentanil in order to counter the painful stimuli resulting from direct laryngoscopy and tracheal intubation by using the NOL index. In order to maximize the clinical relevance of our findings, induction of general anesthesia will be done with standard medications and doses and laryngoscopy will be done with the Macintosh laryngoscope, the most common tool used for intubation in the operating room
Timeline
- Start
- 2018-03-14
- Primary completion
- 2018-10-19
- Completion
- 2021-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remifentanil | Small molecule | 0.5 ug/kg | — |
| Subject | Remifentanil | Small molecule | 1 ug/kg | — |
| Subject | Remifentanil | Small molecule | 1.5 ug/kg | — |
| Subject | Remifentanil | Small molecule | 2 ug/kg | — |
Indications
No indication recorded.